quarter and content is being added weekly.
- Expansion of the Company's Molecular Biology Lab in Dallas and
its facility in Newark, Delaware in response to growth in demand
for both GAT and conventional hybridoma development. This follows
the expansion of the Company's Windham, Maine antibody production
facility during November 2007, which increased capacity for
polyclonal antibody production by 44%.
-- SDI reported the sixth consecutive quarter of double digit
year-over-year growth in the antibody business.
-- SDI reported the third consecutive quarter of more than 20%
year-over-year growth in the food pathogen testing products area.
Matthew H. Knight, the Company's President and Chief Executive Officer,
commented, "SDI has emerged as an established leader in the production of
high-value antibody-based reagents used in the diagnosis of disease, and
our antibody business, based on our new Genomic Antibody Technology(TM), is
gaining widespread adoption in proteomic research, as well as
drug/biomarker discovery among academic, biotech and large pharmaceutical
customers. We reported our sixth consecutive quarter of double-digit
year-over-year revenue growth in antibody-related revenue and this part of
our business is becoming an increasingly important component of our overall
revenue and profitability. For the quarter, antibody revenues expanded to
53% of total revenue compared to 43% in the fourth quarter of 2006."
In 000s Q4 Q4
Revenues $7,271 $6,990
Gross Profit 4,396 3,902
SG&A Expense 3,329
|SOURCE Strategic Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved